INTERNATIONAL PATENT: NUCLIDIUM AG, UNIVERSITY OF BASEL FILES APPLICATION FOR "PROSTATE-SPECIFIC MEMBRANE ANTIGEN RECEPTOR-TARGETING RADIOPHARMACEUTICAL COMPRISING THE [61CU]CU RADIONUCLIDE AND USES THEREOF"

GENEVA, Oct. 1 -- NUCLIDIUM AG (IM ErasmushausBaumleingasse 18CH-4051 Basel), UNIVERSITY OF BASEL (Vizerektorat ForschungPetersgraben 35CH-4001 Basel) filed a patent application (PCT/US2025/021198) for "PROSTATE-SPECIFIC MEMBRANE ANTIGEN RECEPTOR-TARGETING RADIOPHARMACEUTICAL COMPRISING THE [61CU]CU RADIONUCLIDE AND USES THEREOF" on Mar 24, 2025. With publication no. WO/2025/199540, the details related to the patent application was published on Sep 25, 2025.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): JAAFAR-THIEL, Leila (Im ErasmushausBaumleingasse 18CH-4051 Basel), DE ROSE, Francesco (Im Era...